Contact this trialFirst, we need to learn more about you.
Epigenetic Agent
RRx-001 for Neuroendocrine Tumors
Recruiting1 awardPhase 2
Morgantown, West Virginia
This trial is testing whether the epigenetic agent RRx-001 can make patients who have failed a platinum-based doublet regimen respond to reintroduction of that same therapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.